Prevalence and clinical-demographic correlates of hyperhomocysteinemia in inpatients with bipolar disorder in a Han Chinese population

Zhou, Shuang; Zhang, Li Gang; Chen, Hong Mei; Li, Ju Yan; Li, Ran; Zhang, Xi Mei; Wang, Ning; Soares, Jair C.; Cassidy, Ryan M.; Zheng, Yingjun; Ning, Yuping; Wang, Shao Li; Chen, J; Zhang, Xiang Y

doi:10.1016/j.psychres.2017.08.063

Cited by 13 publications

(24 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed that HHcy was highly prevalent in people with schizophrenia (82%) and BD (74%). The abnormal levels of Hcy were also reported by previous studies in patients with schizophrenia and BD ( 19 , 25 , 26 ). Kim et al found that the prevalence of HHcy was 33.8% among Korean patients with schizophrenia ( 41 ).…”

Section: Discussionsupporting

confidence: 84%

See 1 more Smart Citation

Relationship between Serum Homocysteine and Metabolic Syndrome among Patients with Schizophrenia and Bipolar Disorder: A Cross Sectional Study

Feli

Ardekani

Dehghani

2020

IJPS

View full text Add to dashboard Cite

Objective: This study aimed to compare the prevalence of metabolic syndrome and hyperhomocysteinemia and to specify predictors of the metabolic syndrome among patients with schizophrenia and bipolar disorder. Method: This cross sectional study was conducted on 100 patients with schizophrenia and 100 patients with bipolar disorder. The participants' metabolic syndrome was determined according to the criteria set by Third Report of the National Cholesterol Education Program–Adult Treatment Panel III. Hyperhomocysteinemia was considered as homocysteine levels higher than 15 µmol/L. Chi-square test, Fisher's exact test, student t test, Mann-Whitney test, and logistic regression were used for data analysis. Results: The prevalence of metabolic syndrome was not significantly different (P = 0.07) between patients with schizophrenia (27%) and bipolar disorder (39%). No statistically significant difference (P = 0.17) was observed between patients with schizophrenia (82%) and bipolar disorder (74%) in the prevalence of hyperhomocysteinemia. The results of multivariable logistic regression model showed a significant association of smoking and BMI with metabolic syndrome in patients with schizophrenia (OR = 3.69, 95% CI: 1.13-12.05, and OR = 1.38, 95% CI: 1.20-1.60, respectively). In patients with bipolar disorder, BMI was a significant predictor of developing metabolic syndrome (OR = 1.29, 95% CI: 1.14-1.47). Metabolic syndrome was more prevalent in women than in men in both diagnostic groups (P < 0.05). No significant difference was observed in hyperhomocysteinemia prevalence between male and female patients with schizophrenia (P = 1.00). However, hyperhomocysteinemia was more prevalent in males than in females among patients with bipolar disorder (P = 0.001). Conclusion: Findings showed a high prevalence of metabolic syndrome and hyperhomocysteinemia among patients with schizophrenia and bipolar disorder. To deal with this problem, regular monitoring and conducting early interventions are recommended to determine the metabolic risk profile and to prevent the cardiovascular diseases.

show abstract

Section: Discussionsupporting

confidence: 84%

“…Mabrouk et al stated that HHcy was present in 34.4% of the patients with schizophrenia in Tunisia ( 24 ). Zhou et al reported that the prevalence of HHcy was 34.8% among Chinese patients with BD ( 25 ). Some investigators have also shown a relationship between HHcy and MetS among individuals with schizophrenia and BD.…”

mentioning

confidence: 99%

Relationship between Serum Homocysteine and Metabolic Syndrome among Patients with Schizophrenia and Bipolar Disorder: A Cross Sectional Study

Feli

Ardekani

Dehghani

2020

IJPS

View full text Add to dashboard Cite

show abstract

“…Moreover, Hcy concentration in male patients treated with this medication was lower. These findings are consistent with our previous study (Zhou et al, ) and extend them to the field of sex differences. Also, our results are partially similar to those observed in a previous study by Levine et al showing that patients taking valproate had slightly (not significantly) lower Hcy levels than those without taking valproate (Levine et al, ).…”

Section: Discussionsupporting

confidence: 94%

“…Improving the understanding of sex differences in Hcy of BD has great clinical relevance to the treatment approaches and responses with BD patients. Interestingly, in one of our recent studies, we found sex differences in the prevalence of HHcy in BD, showing higher Hcy levels in male than female patients (Zhou et al, ). In the current study, we further explored sex differences in clinical associated risk factors for HHcy rate and Hcy levels in Chinese patients with BD.…”

Section: Introductionmentioning

confidence: 72%

“…likely to exhibit HHcy (Permoda-Osip, Dorszewska, Skibinska, Chlopocka-Wozniak, & Rybakowski, 2013;Permoda-Osip, Kisielewski, Dorszewska, & Rybakowski, 2014) or have higher levels of Hcy (Dias, Brissos, Cardoso, Andreazza, & Kapczinski, 2009;Sanchez-Autet et al, 2018) than female patients during bipolar depressive episodes, suggesting that sex-associated differences in HHcy exist in patients with BD. Recently, our groups also found that there were sex differences in the prevalence of HHcy and plasma Hcy levels in BD patients (Zhou et al, 2018). However, the pathophysiological mechanisms underlying these phenomena are still unclear.…”

mentioning

confidence: 83%

See 1 more Smart Citation

Sex differences in the prevalence and clinical correlates of hyperhomocysteinemia in patients with bipolar disorder

Lin

Huang

et al. 2020

Human Psychopharmacology

Self Cite

View full text Add to dashboard Cite

Objective Sex differences in bipolar disorder are well recognized but little attention has been paid to sex differences in homocysteine or hyperhomocysteinemia in bipolar patients. This study compared gender differences in homocysteine levels and rates of hyperhomocysteinemia in Chinese inpatients with bipolar disorder. Methods A total of 198 BD patients and 84 healthy controls were enrolled. The Young Mania Rating Scale, Hamilton Depression Rating Scale, and the Clinical Global Impressions–Severity scale were used to assess the affective symptomatology. Fasting plasma Hcy levels were measured by high‐performance liquid chromatography. Results Men had higher homocysteine levels than women and the prevalence of hyperhomocysteinemia in male patients was approximately twice that in female patients. Logistic regression analyses showed that HHcy was associated with less frequent use of valproate in males and being overweight in females. Further correlation analysis and multivariate regression analysis demonstrated that Hcy levels were inversely correlated with valproate treatment in men and positively associated with overweight in women. Conclusions In bipolar patients, there are significant differences between sexes in the levels of homocysteine and prevalence of hyperhomocysteinemia. This appears to be associated with lower prevalence of valproate prescribing in men and with being overweight in women.

show abstract

Liraglutide Ameliorates Hyperhomocysteinemia-Induced Alzheimer-Like Pathology and Memory Deficits in Rats via Multi-molecular Targeting

Zhang

Xie²,

et al. 2019

Neurosci. Bull.

View full text Add to dashboard Cite

Prevalence and clinical-demographic correlates of hyperhomocysteinemia in inpatients with bipolar disorder in a Han Chinese population

Cited by 13 publications

References 43 publications

Relationship between Serum Homocysteine and Metabolic Syndrome among Patients with Schizophrenia and Bipolar Disorder: A Cross Sectional Study

Relationship between Serum Homocysteine and Metabolic Syndrome among Patients with Schizophrenia and Bipolar Disorder: A Cross Sectional Study

Sex differences in the prevalence and clinical correlates of hyperhomocysteinemia in patients with bipolar disorder

Liraglutide Ameliorates Hyperhomocysteinemia-Induced Alzheimer-Like Pathology and Memory Deficits in Rats via Multi-molecular Targeting

Contact Info

Product

Resources

About